China's first bone and soft tissue tumor NGS expert consensus to help clinical precision diagnosis and treatment

BEIJING, November 26, 2021/PRNewswire/ - Bone and soft tissue tumors are a type of high malignant tumors, which are more likely to occur in adolescents and middle-aged people.

With the rapid development of precision medicine, clinical tumor diagnosis and treatment has entered the molecular level

This consensus is closely integrated with clinical practice, from the application guidance of NGS testing in the diagnosis and treatment of bone and soft tissue tumors, to the specimen types and process specifications for NGS testing, and the clinical interpretation of NGS testing reports.

Professor Niu Xiaohui, a member of the consensus expert group and the Department of Orthopedic Oncology, Beijing Jishuitan Hospital, said, “NGS testing provides a new and powerful tool for the clinical diagnosis and treatment of bone and soft tissue tumors

Professor Jingnan Shen from the Department of Orthopedic Oncology, the First Affiliated Hospital of Sun Yat-sen University, a member of the consensus expert group, said, “NGS testing has different meanings and values ​​in different stages of bone and soft tissue tumor risk management.

Regarding the clinical value of this consensus, Professor Cai Zhengdong, a member of the consensus expert group and the Department of Orthopedics, Shanghai First People’s Hospital, commented, “With the progress of molecular biology and tumor treatment, next-generation sequencing has gradually become a hot spot, not just a professional Clinicians, with the improvement of the public knowledge level in the information age, patients will actually have this aspect

As a representative domestic company providing NGS testing services, Simcere Diagnostics supported the preparation of this consensus throughout the entire process